Evidence map›Paper›PMID 32942764›Full record

ArticleInternational journal of molecular sciences2020

Oxidative Oligomerization of DBL Catechol, a potential Cytotoxic Compound for Melanocytes, Reveals the Occurrence of Novel Ionic Diels-Alder Type Additions.

Manickam Sugumaran, Kubra Umit, Jason Evans, Rachel Muriph, Shosuke Ito, Kazumasa Wakamatsu

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Manickam SugumaranDepartment of Biology, University of Massachusetts, Boston, MA 02125, USA.ORCID 0000-0003-1508-9020
Kubra UmitDepartment of Biology, University of Massachusetts, Boston, MA 02125, USA.ORCID 0000-0002-3063-2143
Jason EvansDepartment of Chemistry, University of Massachusetts, Boston, MA 02125, USA.
Rachel MuriphDepartment of Chemistry, University of Massachusetts, Boston, MA 02125, USA.
Shosuke ItoDepartment of Chemistry, Fujita Health University School of Medical Sciences, Toyoake, Aichi 451-0052, Japan.ORCID 0000-0001-9182-5144
Kazumasa WakamatsuDepartment of Chemistry, Fujita Health University School of Medical Sciences, Toyoake, Aichi 451-0052, Japan.ORCID 0000-0003-1748-9001
University of Massachusetts Boston · USFujita Health University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The exposure of human skin to 4-(4-hydroxyphenyl)-2-butanone (raspberry ketone, RK) is known to cause chemical/occupational leukoderma. RK is a carbonyl derivative of 4-(4-hydroxyphenyl)-2-butanol (rhododendrol), a skin whitening agent that was found to cause leukoderma in skin of many consumers. These two phenolic compounds are oxidized by tyrosinase and the resultant products seem to cause cytotoxicity to melanocytes by producing reactive oxygen species and depleting cellular thiols through

Indexed as

BenzoquinonesButanonesCatecholsHumansMelanocytesMonophenol MonooxygenaseOxidation-ReductionOxidative StressPolymerizationReactive Oxygen SpeciesSkinSkin Lightening PreparationsSulfhydryl CompoundsBenzoquinonesButanonescatecholCatecholsMonophenol Monooxygenasequinoneraspberry ketoneReactive Oxygen SpeciesSkin Lightening PreparationsSulfhydryl Compounds3,4-dihydroxybenzalacetoneDBL catecholionic Diels-Alder additionleukodermamelanotoxicityraspberry ketonerhododendrol toxicityskin lightening compounds

Identifiers

PMID32942764
PMCPMC7555913
OpenAlexW3086044291

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.